Decoding Breast Cancer Genes: Fresh vs. Archived Tissues
"Can we reliably use old tissue samples to guide modern breast cancer treatment?"
In the fight against breast cancer, understanding the unique genetic makeup of a tumor is crucial. Gene expression profiling, which analyzes the activity levels of different genes, has become a powerful tool for identifying potential diagnostic and therapeutic targets. This information can help doctors classify breast cancers, predict how they will respond to treatment, and tailor therapies accordingly.
However, a significant hurdle lies in the availability of suitable tissue samples for these analyses. While fresh frozen (FF) tissue provides the most accurate snapshot of a tumor's gene expression, it's often challenging to obtain and store in large quantities. On the other hand, formalin-fixed, paraffin-embedded (FFPE) samples, which are routinely collected and stored in pathology archives, represent a vast resource of clinical information. But, the process of preserving these FFPE samples can degrade RNA, the molecule that carries genetic information, making it difficult to analyze.
This article explores the challenges and potential solutions of using FFPE tissue for gene expression profiling. We'll dive into a study that compares gene expression data from matched FF and FFPE breast cancer samples, investigates different normalization strategies to correct for RNA degradation, and ultimately, helps guide the development of reliable diagnostic tests using archived tissues.
Archival Tissue as a Research Resource
Research has shown that true archival formalin-fixed, paraffin-embedded (FFPE) breast cancer tissues can support RNA sequencing and help distinguish estrogen receptor-positive (ER+) from estrogen receptor-negative (ER-) cases. One study evaluated gene-expression fidelity by comparing FFPE results with publicly available fresh-tissue databases. Other work found that many decade-old FFPE samples from different institutions and processing histories can yield RNA suitable for gene-expression profiling.
Methods and Their Constraints
FFPE gene-expression analysis is an established approach, but formalin fixation and paraffin embedding can cause oxidation, cross-linking, and other chemical modifications that reduce RNA quality. In archival FFPE breast cancer samples, single-gene analysis is reported to be limiting, whereas targeted gene-set approaches can distinguish ER+ from ER- tumors more effectively. A 2025 comparison also reported that one sequencing kit achieved gene-expression quantification comparable to another with 20-fold less RNA input, although it required greater sequencing depth.
A Developing Research Tradition
The field has progressed from relying mainly on fresh tissue toward asking whether archived, fixed specimens can support molecular analysis. This transition has encouraged researchers to refine extraction, library-preparation, and interpretation methods for degraded material. Because the supplied sources do not document a specific historical timeline, these milestones should be viewed as a broad description rather than a complete history.
The FFPE Challenge: RNA Degradation and Normalization
The main issue with FFPE samples is that the RNA within them is often degraded. Think of RNA as a delicate string of beads. The preservation process can chop those strings into smaller pieces, making it harder to get an accurate reading of gene expression. The study confirms this, showing a noticeable shift in raw cycle threshold (Cq) values – a measure of gene expression – in FFPE samples compared to FF samples. Higher Cq values in FFPE indicate lower RNA integrity due to degradation.
- geNorm: Identifies the most stable genes across a set of samples to use as controls.
- NormFinder: Selects the best single control gene or combination of two genes, considering different sample subgroups (FF vs. FFPE).
- Mean Cq per sample: Uses the average expression level of all genes in a sample as a normalization factor.
- NorMean: A new model developed in the study that combines the coefficient of variation (CV) and Pearson correlation coefficient to identify stable control genes.
Current Research Direction
Recent work is increasingly focused on making gene-expression and genomic analysis practical for archived breast cancer tissue. Researchers are examining how preparation methods, RNA input, sequencing depth, and analytical strategies affect results. The available material does not establish a single best workflow, so current findings should be treated as an evolving research area.
Where FFPE Analysis Falls Short
The principal limitation is that fixation and embedding can damage or chemically alter RNA, complicating reliable measurement. Analyses based on individual genes may be especially vulnerable to these limitations, making broader targeted gene-set strategies more useful in some settings. These constraints mean that successful sequencing of an FFPE sample does not automatically guarantee that every type of downstream interpretation will be equally reliable.
Fresh Frozen Versus FFPE
Several studies have directly compared RNA-sequencing results from matched fresh frozen and FFPE breast cancer tissues. The comparisons used library-preparation protocols to evaluate how tissue preservation and small starting amounts of RNA influence gene-expression results. This design provides a direct framework for judging archived tissue against fresh frozen material rather than treating the two sources as interchangeable by assumption.
The Future of FFPE in Breast Cancer Diagnostics
The researchers found that normalization works best for genes that are moderately to highly expressed and show significant variation between samples. These genes are more likely to provide reliable information, even when extracted from FFPE tissue. However, some genes consistently failed to correlate between FF and FFPE samples, regardless of the normalization method used.
A Careful Balance
The available evidence supports a balanced view of fresh and archived breast cancer tissue. FFPE samples can preserve valuable material for molecular research, but fixation-related damage and analytical limitations require careful interpretation. Expert conclusions should therefore account for tissue history, assay design, and the specific biological question being studied.
Toward Better Archived-Tissue Analysis
Future research will likely focus on improving workflows that recover dependable molecular information from limited or degraded specimens. Progress may come from better sample preparation, sequencing strategies, and analytical methods that evaluate gene sets or broader molecular patterns. The supplied sources do not establish a specific future technology or forecast, so these possibilities remain appropriately cautious.
Heterogeneity and Molecular Context
Spatial profiling can reveal substantial heterogeneity within FFPE breast cancer tissue. In one sample, the Visium CytAssist study identified three molecularly distinct tumor subtypes and used them to define cell neighborhoods and biomarkers associated with progression toward invasive carcinoma. At the same time, archival-tissue analysis may require targeted gene-set approaches because single-gene analysis can be limiting.
From Archives to Patient Evidence
Using FFPE breast cancer tissue for genomic and gene-expression analysis could help researchers study real-world clinical specimens that were collected retrospectively. A 2024 study specifically assessed the feasibility of such a workflow using FFPE breast cancer tissue. This creates opportunities to learn from existing patient material, while the practical value of any result still depends on specimen quality and the reliability of the analytical method.
This highlights a critical point: not all genes are suitable for clinical tests based on FFPE samples. Genes that show poor correlation should be excluded from consideration to avoid inaccurate results and potentially flawed treatment decisions.
Ultimately, this research provides valuable guidance for developing clinical diagnostic tests that leverage the vast archive of FFPE tissues. By carefully selecting genes and applying appropriate normalization strategies, scientists can unlock the wealth of information stored within these samples, paving the way for more personalized and effective breast cancer treatments.